Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL888002 | 0.97 | MEN1 (0.49) | ATMMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL3838857 | 0.96 | MEN1 (0.47) | ATMMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL8673442 | 0.93 | MEN1 (0.49) | ATMMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL7691355 | 0.90 | MEN1 (0.47) | ATMMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL326451 | 0.89 | MEN1 (0.46) | ATMMEN1MAPTKMT2AL3MBTL1 | |
| Acetic Acid SCHEMBL169983 | 0.86 | MAPT (0.40) | ATMMEN1MAPTKMT2AL3MBTL1 | |
| Acetic Acid SCHEMBL5227791 | 0.86 | MEN1 (0.47) | ATMMEN1MAPTKMT2AL3MBTL1 | |
| Acetic Acid SCHEMBL6697326 | 0.86 | MEN1 (0.49) | ATMMEN1MAPTKMT2AL3MBTL1 | |
| Acetic Acid SCHEMBL18104019 | 0.86 | MEN1 (0.49) | ATMMEN1MAPTKMT2AL3MBTL1 | |
| Acetic Acid SCHEMBL4292824 | 0.85 | MEN1 (0.35) | ATMMEN1MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-2562155-B1 | HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2019-06-05 | — | — | EP | disclosed |
| EP-3480198-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-8993616-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| WO-2005068410-A1 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-09-30 | — | — | US | disclosed |
| US-6790971-B1 | AMIDE OR CARBAMATE FUNCTION AT 11 BETA-POSITION; CLAIMED 3-ONE-DIENE INTERMEDIATE HAS HYDROXYMETHYLALKYL GROUP ON 11 POSITION; ANTIPROGESTOMIMETIC; HORMONE-DEPENDENT TUMORS; ANIMAL HUSBANDRY | AVENTIS PHARMA S.A. (FR) | 2004-09-14 | — | — | US | disclosed |
| US-5707982-A | ANTITUMOR | ROUSSEL UCLAF (FR) | 1998-01-13 | — | — | US | disclosed |
| US-5668282-A | 4,5-cyclicimidazo[1,5-A]quinoxalines | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5574038-A | 5,6-cyclicimidazo [1,5-a] Quinoxalines | THE UPJOHN COMPANY (US) | 1996-11-12 | — | — | US | disclosed |
| US-5541324-A | Imidazo[1,5-A]quinoxalines | THE UPJOHN COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| US-5290771-A | 19-nor-steroids | ROUSSEL UCLAF (FR) | 1994-03-01 | — | — | US | disclosed |
| WO-1992022552-A1 | IMIDAZO[1,5-a]QUINOXALINES | THE UPJOHN COMPANY (US) | 1992-12-23 | — | — | WO | disclosed |
| US-5149696-A | Antiestrogens | ROUSSEL UCLAF (FR) | 1992-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | LCT, AGXT, HDAC9 | ATM 4708/4885MEN1 4264/4885MAPT 4793/4885 |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | ATM 4875/4885MEN1 1930/4885MAPT 3374/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | ATM 4863/4885MEN1 2535/4885MAPT 3361/4885 |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | ATM 1113/4885MEN1 2176/4885MAPT 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.